A citation-based method for searching scientific literature

Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
Times Cited: 4544







List of co-cited articles
510 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
27


Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P Day,[...]. J Hepatol 2018
589
14

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
13

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
963
12

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
Stefano Romeo, Julia Kozlitina, Chao Xing, Alexander Pertsemlidis, David Cox, Len A Pennacchio, Eric Boerwinkle, Jonathan C Cohen, Helen H Hobbs. Nat Genet 2008
12

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
897
10

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias. J Hepatol 2017
449
10

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal. Hepatology 2018
842
10

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
9

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Zobair M Younossi, Pegah Golabi, Leyla de Avila, James Minhui Paik, Manirath Srishord, Natsu Fukui, Ying Qiu, Leah Burns, Arian Afendy, Fatema Nader. J Hepatol 2019
583
9

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis. Metabolism 2016
9

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias, Rolf Hultcrantz. Hepatology 2015
8


The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
Leon A Adams, James F Lymp, Jenny St Sauver, Schuyler O Sanderson, Keith D Lindor, Ariel Feldstein, Paul Angulo. Gastroenterology 2005
8

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.
Giorgio Bedogni, Stefano Bellentani, Lucia Miglioli, Flora Masutti, Marilena Passalacqua, Anna Castiglione, Claudio Tiribelli. BMC Gastroenterol 2006
7

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Paul Angulo, Jason M Hui, Giulio Marchesini, Ellisabetta Bugianesi, Jacob George, Geoffrey C Farrell, Felicity Enders, Sushma Saksena, Alastair D Burt, John P Bida,[...]. Hepatology 2007
7

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
7

Mechanisms and disease consequences of nonalcoholic fatty liver disease.
Rohit Loomba, Scott L Friedman, Gerald I Shulman. Cell 2021
190
7

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
7

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.
Julia Kozlitina, Eriks Smagris, Stefan Stender, Børge G Nordestgaard, Heather H Zhou, Anne Tybjærg-Hansen, Thomas F Vogt, Helen H Hobbs, Jonathan C Cohen. Nat Genet 2014
669
7

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.
Zobair Younossi, Maria Stepanova, Janus P Ong, Ira M Jacobson, Elisabetta Bugianesi, Ajay Duseja, Yuichiro Eguchi, Vincent W Wong, Francesco Negro, Yusuf Yilmaz,[...]. Clin Gastroenterol Hepatol 2019
350
7

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Zobair M Younossi, Deirdre Blissett, Robert Blissett, Linda Henry, Maria Stepanova, Youssef Younossi, Andrei Racila, Sharon Hunt, Rachel Beckerman. Hepatology 2016
593
6

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Kenneth Cusi, Beverly Orsak, Fernando Bril, Romina Lomonaco, Joan Hecht, Carolina Ortiz-Lopez, Fermin Tio, Jean Hardies, Celia Darland, Nicolas Musi,[...]. Ann Intern Med 2016
492
6

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
917
6

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
317
6

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
994
6

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Giovanni Targher, Christopher D Byrne, Amedeo Lonardo, Giacomo Zoppini, Corrado Barbui. J Hepatol 2016
642
6

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Siddharth Singh, Alina M Allen, Zhen Wang, Larry J Prokop, Mohammad H Murad, Rohit Loomba. Clin Gastroenterol Hepatol 2015
813
6


Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.
Jeong-Hoon Lee, Donghee Kim, Hwa Jung Kim, Chang-Hoon Lee, Jong In Yang, Won Kim, Yoon Jun Kim, Jung-Hwan Yoon, Sang-Heon Cho, Myung-Whun Sung,[...]. Dig Liver Dis 2010
543
6

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
Christopher D Williams, Joel Stengel, Michael I Asike, Dawn M Torres, Janet Shaw, Maricela Contreras, Cristy L Landt, Stephen A Harrison. Gastroenterology 2011
6


Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
Quentin M Anstee, Giovanni Targher, Christopher P Day. Nat Rev Gastroenterol Hepatol 2013
6

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Parambir S Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr,[...]. Hepatology 2017
846
6

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
Jie Li, Biyao Zou, Yee Hui Yeo, Yuemin Feng, Xiaoyu Xie, Dong Hyun Lee, Hideki Fujii, Yuankai Wu, Leslie Y Kam, Fanpu Ji,[...]. Lancet Gastroenterol Hepatol 2019
302
6

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
Vincent Wai-Sun Wong, Wah-Kheong Chan, Shiv Chitturi, Yogesh Chawla, Yock Young Dan, Ajay Duseja, Jiangao Fan, Khean-Lee Goh, Masahide Hamaguchi, Etsuko Hashimoto,[...]. J Gastroenterol Hepatol 2018
214
5

Treatment of NAFLD with diet, physical activity and exercise.
Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell. J Hepatol 2017
503
5

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Renata Belfort, Stephen A Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin Tio, Joseph Pulcini,[...]. N Engl J Med 2006
5

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
Giulio Marchesini, Elisabetta Bugianesi, Gabriele Forlani, Fernanda Cerrelli, Marco Lenzi, Rita Manini, Stefania Natale, Ester Vanni, Nicola Villanova, Nazario Melchionda,[...]. Hepatology 2003
5

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
Stuart McPherson, Tim Hardy, Elsbeth Henderson, Alastair D Burt, Christopher P Day, Quentin M Anstee. J Hepatol 2015
609
5

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, Herbert Tilg, Christopher D Byrne, Giovanni Targher. Gut 2021
103
5

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
Richard K Sterling, Eduardo Lissen, Nathan Clumeck, Ricard Sola, Mendes Cassia Correa, Julio Montaner, Mark S Sulkowski, Francesca J Torriani, Doug T Dieterich, David L Thomas,[...]. Hepatology 2006
5

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Gastroenterology 2019
508
5

Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
Fasiha Kanwal, Jennifer R Kramer, Liang Li, Jianliang Dai, Yamini Natarajan, Xian Yu, Steven M Asch, Hashem B El-Serag. Hepatology 2020
78
6

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Zobair M Younossi, Munkhzul Otgonsuren, Linda Henry, Chapy Venkatesan, Alita Mishra, Madeline Erario, Sharon Hunt. Hepatology 2015
449
5

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.
Yuichiro Eguchi, Hideyuki Hyogo, Masafumi Ono, Toshihiko Mizuta, Naofumi Ono, Kazuma Fujimoto, Kazuaki Chayama, Toshiji Saibara. J Gastroenterol 2012
312
5

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.
Vincent Wai-Sun Wong, Julien Vergniol, Grace Lai-Hung Wong, Juliette Foucher, Henry Lik-Yuen Chan, Brigitte Le Bail, Paul Cheung-Lung Choi, Mathurin Kowo, Anthony Wing-Hung Chan, Wassil Merrouche,[...]. Hepatology 2010
817
4

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Qing Ye, Biyao Zou, Yee Hui Yeo, Jie Li, Daniel Q Huang, Yuankai Wu, Hongli Yang, Chuanli Liu, Leslie Y Kam, Xiang Xuan Eunice Tan,[...]. Lancet Gastroenterol Hepatol 2020
200
4

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
Amy G Shah, Alison Lydecker, Karen Murray, Brent N Tetri, Melissa J Contos, Arun J Sanyal. Clin Gastroenterol Hepatol 2009
754
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.